SharePost Content Read More Yahoo Finance #finance Post navigation AbbVie beats Q1 2026 earnings, raises full-year forecast Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide